Patent application number | Description | Published |
20090123472 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 05-14-2009 |
20090155234 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, MX1 - A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided. | 06-18-2009 |
20090186028 | Detection of mutations in a gene associated with resistance to viral infection - A method for detecting a mutation related to the gene encoding LDLR. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human LDLR, including antisense oligonucleotides, methods, and compositions specific for human LDLR, are also provided. | 07-23-2009 |
20090291074 | MUTATIONS IN OAS1 GENES - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 11-26-2009 |
20110071073 | Detection of mutations in a gene associated with resistance to viral infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 03-24-2011 |
20110237501 | Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 09-29-2011 |
20120070424 | Mutations on OAS1 Genes - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 03-22-2012 |
20120253027 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WTIH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 10-04-2012 |
20120258908 | OLIGOADENYLATE SYNTHETASE (OAS) - The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention. | 10-11-2012 |
20120321608 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 12-20-2012 |
20130142773 | Mutations in OAS1 Genes - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 06-06-2013 |
20140005101 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |
20140005102 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |
20140037717 | Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 02-06-2014 |